Recombinant antibody production leverages Chinese hamster ovary (CHO) cells due to their efficiency in expressing complex proteins. Improving these processes involves modifying various factors, including cell line engineering, media formulation, and bioreactor settings. A key goal is to maximize antibody titer while lowering production expenses and